Issue
Alert me when new journal issues are available via or via
EVIDENCE-BASED ONCOLOGY
Combined androgen blockade may have long term survival benefits over monotherapy, but may increase adverse effects and reduce quality of life in advanced prostate cancer: Abstracted from: Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95:361–376. H Akaza page 223 Full Text | Full-Text PDF (38 KB)
Editorial board page CO2 Full-Text PDF (48 KB)
Editorial to: Cancer treatment reviews and the Cochrane collaboration page 149 Full Text | Full-Text PDF (35 KB)
Early diagnosis and surgical management of prostate cancer Kate D Linton, Freddie C Hamdy pages 151-160 Abstract | Full Text | Full-Text PDF (124 KB)
Radical radiotherapy for prostate cancer C.C Parker, D.P Dearnaley pages 161-169 Abstract | Full Text | Full-Text PDF (232 KB)
Current strategies in the management of hormone refractory prostate cancer Cynthia L Martel, Paul H Gumerlock, Frederick J Meyers, Primo N Lara pages 171-187 Abstract | Full Text | Full-Text PDF (267 KB)
Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment Colby L Eaton, R.E Coleman pages 189-198 Abstract | Full Text | Full-Text PDF (161 KB)
Immunotherapy and prostate cancer Joseph M Kaminski, James B Summers, Matthew B Ward, Mark R Huber, Boris Minev pages 199-209 Abstract | Full Text | Full-Text PDF (146 KB)
Management of treatment-related osteoporosis in men with prostate cancer Matthew R Smith pages 211-218 Abstract | Full Text | Full-Text PDF (103 KB)
Conformal radiotherapy with dose escalation appears safe and effective in localised prostate cancer: Abstracted from: Brundage M, Lukka H, Crook J, et al. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer—a systematic review. Radiother Oncol 2002; 64: 239–50. Eric M Horwitz pages 219-221 Full Text | Full-Text PDF (64 KB)
EVIDENCE–BASED ONCOLOGY
Early androgen suppression may reduce disease progression and improve long term survival compared with deferred androgen suppression in locally advanced prostate cancer: Abstracted from: Wilt T, Nair B, MacDonald R, et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer (Cochrane Review). The Cochrane Library, Issue 1, 2003. Oxford: Update Software. Hideyuki Akaza pages 224-225 Full Text | Full-Text PDF (50 KB)
Adding androgen suppression to radiotherapy may improve disease-free survival over radiotherapy alone in locally advanced prostate cancer: Abstracted from: Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–6. John B Fiveash pages 227-229 Full Text | Full-Text PDF (71 KB)
Radical prostatectomy may improve disease-specific mortality, but not overall survival compared with watchful waiting in early prostate cancer: Abstracted from: Holmberg L, Bill-Axelson A, Helgesen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 103–6 Darrel E Drachenberg pages 231-233 Full Text | Full-Text PDF (65 KB)
Overall, watchful waiting and radical prostatectomy have similar quality of life in localised prostate cancer: Abstracted from: Steineck G, Helgesen F, Adolfsson J et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790–96 Darrel E Drachenberg pages 235-237 Full Text | Full-Text PDF (61 KB)
Articles to appear in forthcoming issues page 239 Full-Text PDF (23 KB)
Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
